What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%

Lori Anne Kunkel, Director of Enliven Therapeutics (NASDAQ:ELVN), reported the sale of 10,000 shares of common stock for a total consideration of approximately $345,000 on June 5, 2026, according to a SEC Form 4 filing.

Post-transaction value (direct ownership)

Transaction value based on SEC Form 4 weighted average purchase price ($34.54); post-transaction value based on June 5, 2026 market close.

How does this transaction align with Kunkel's historical trading activity?This sale marks Kunkel's first open-market disposition of Enliven Therapeutics common stock, following a history of administrative filings with no prior open-market sales reported.

What portion of Kunkel's total direct holdings was affected?The transaction represented 16% of her direct common stock holdings, reducing her stake from 61,884 to 51,884 shares, with no impact on any indirect or derivative positions.

Was the transaction executed under a pre-arranged plan?Yes, the Form 4 notes that the sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2026.

What is the market context for this sale?As of June 5, 2026, Enliven Therapeutics shares had returned 62.4% over the prior y

Fuente original: Yahoo Finance (https://finance.yahoo.com/markets/stocks/articles/know-345-000-enliven-insider-195642613.html)